Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Select Equities China Conference 2021 – 5th Annual Institutional Conference
16 slides from Vita Life Sciences's conference presentation, Oct 27, 2021
Slide 1: Select Equities China Conference
For personal use only SELECT EQUITIES CHINA CONFERENCE 5th ANNUAL INSTITUTIONAL CONFERENCE 28th OCTOBER 2021
Slide 2: Managing Director's Review
MANAGING DIRECTOR’S For personal use only REVIEW ANDREW O’KEEFE MANAGING DIRECTOR Mr O’Keefe was appointed Managing Director on 1st January 2017. Mr O’Keefe has over 20 years’ experience within the Australian pharmaceutical and healthcare industry. During his career Mr O’Keefe has held senior leader
Slide 3: Vita Life Sciences (VLS)
VITA LIFE SCIENCES (VLS) For personal use only Vita Life Sciences is an Australian SHARE PRICE (NOV 2020-OCT 2021) owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the development and distribution of over the counter (OTC) medicines, as we
Slide 4: Leadership Team
LEADERSHIP TEAM For personal use only ANDREW O’KEEFE CHIN L KHOO SHAUN RUTHERFORD MELISSA PEREIRA KS BEH MANAGING DIRECTOR CHIEF FINANCIAL OFFICER GLOBAL SALES DIRECTOR HEAD OF MARKETING GENERAL MANAGER, MALAYSIA & SINGAPORE RENEE TI SUAT LING KOAY JUNE LAU SANDRA VELASQUEZ ALEXANDRA WARD SENIOR COR
Slide 5: Overview, Values and History
OVERVIEW VALUES Vita Life Sciences is a multinational healthcare Vita Life Sciences has a companywide commitment to: For personal use only company involved in the formulation and • Focus its efforts on the health and well-being of customers distribution of high quality vitamins and • Conduct activit
Slide 6: VLS Markets
VLS MARKETS For personal use only China Market Population 2020 China Revenue (A$’M) Market Population 2020 Revenue (A$’M) Australia* 26 20.8 Vietnam Australia* 26 20.8 Thailand Vietnam Malaysia 33 16.9 Thailand Malaysia 33 16.9 Singapore 6 4.9 Malaysia Singapore 6 4.9 Singapore Malaysia Singapore Vi
Slide 7: Product Portfolio
PRODUCT PORTFOLIO For personal use only Nervous System Children’s Health Nutritional Oils Immunity Hair, Skin & Nails Liver & Digestion Nutritionals Weight Management Cardiovascular Health Pain & Inflammation Pregnancy & Breastfeeding Men’s Health Women’s Health Antioxidants Bones & Joints SELECT EQ
Slide 8: Branding
BRANDING For personal use only SELECT EQUITIES CHINA CONFERENCE – 5th ANNUAL INSTITUTIONAL CONFERENCE 28th OCTOBER 2021 8
Slide 9: China Business Model
CHINA BUSINESS MODEL For personal use only • Launched in 2020 a direct to China (CBEC) model • Exclusive partnership with a distributor based in Nanjing • Strategy provides a simplified route to market • Reduces channel conflict including stronger controls across the supply chain • Year on year grow
Slide 10: Advertising in China
ADVERTISING IN CHINA For personal use only SELECT EQUITIES CHINA CONFERENCE – 5th ANNUAL INSTITUTIONAL CONFERENCE 28th OCTOBER 2021 10
Slide 11: Look-Back Growth Delivered
LOOK-BACK GROWTH DELIVERED For personal use only 3 years ago the business implemented a strategic plan to stimulate sales after consistent periods of stagnant growth 2020 the strategic plan delivered over 1000 new retail customers and record sales revenue of $46.5m with an average growth rate of 5.7
Slide 12: FY December 2020 Highlights
FY DECEMBER 2020 HIGHLIGHTS For personal use only 3 Record Group sales of $46.5m, an increase of 9.5% on PCP 3 New distribution channels delivered record sales performance across key markets in Australia and Malaysia 3 Immunity products supporting consumers health and wellbeing during COVID -19 stim
Slide 13: Key Financial Highlights
KEY FINANCIAL HIGHLIGHTS 2021 FIRST HALF For personal use only 3 Record first half revenue of $25.7 million, up 17% on prior corresponding period (PCP) GROUP SALES GROUP EBIT reflecting impact of increased channels of distribution A$’m A$’m 27 5 3 Strong brand representation across all major E-comme
Slide 14: Future Investment Pillars
FUTURE INVESTMENT PILLARS For personal use only Brand building Education and Talent wellbeing Operational Innovation leverage Group investment Group investment to Group investment on Group investment on strategy to drive deliver a high quality talent acquisition to ERP integration across consumer &
Slide 15: Outlook
For personal use only OUTLOOK • Several strategic initiatives initiated in 2020 are driving stronger domestic and Asian sales. The Group is benefiting from increased consumer interest and purchases across most categories in its major markets, Australia, Malaysia and Singapore. • The sales growth of
Slide 16: Thank You
THANK YOU For personal use only DISCLAIMER: This document has been prepared Certain statements in this presentation are or implied) is given or made by Vita Life Sciences Subject to any continuing obligation under by Vita Life Sciences Limited (Vita Life Sciences) and forward looking statements that